^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SSTR2 inhibitor

    Related drugs:
    27d
    Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors. (PubMed, J Neuroendocrinol)
    Overall, these findings suggest that the efficacy and safety of [177Lu]Lu-edotreotide are in line with those reported for other RPTs in similar clinical settings. Clinical Trial Registration: PROSPERO 2024 CRD42024518028.
    Retrospective data • Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    Solucin (177Lu-edotreotide)
    3ms
    67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma (clinicaltrials.gov)
    P1/2, N=21, Terminated, Clarity Pharmaceuticals Ltd | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial primary completion date
    |
    Sartate (67Cu MeCOSar octreotate)
    3ms
    START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
    P3, N=300, Recruiting, Lund University Hospital | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    capecitabine • Solucin (177Lu-edotreotide)
    3ms
    67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma (clinicaltrials.gov)
    P1/2, N=21, Terminated, Clarity Pharmaceuticals Ltd | N=34 --> 21 | Trial completion date: Dec 2028 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2028 --> Oct 2024; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Sartate (67Cu MeCOSar octreotate)
    4ms
    Satoreotide Theranostic Pilot study in Extensive Stage in Small Cell Lung Cancer (ES-SCLC) (ACTRN12623000185662)
    P1, N=70, Active, not recruiting, Ariceum Therapeutics Australia Pty Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SOMther (lutetium-177 DOTA satoreotide)
    4ms
    The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors. (PubMed, Semin Nucl Med)
    In this article, we review both preclinical and clinical data evaluating the efficacy and safety of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in the treatment of neuroendocrine tumors. We also provide a brief overview of other SSTR antagonists currently under investigation.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    SOMther (lutetium-177 DOTA satoreotide)
    6ms
    177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    New P1/2 trial
    |
    EBTATE
    6ms
    Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (clinicaltrials.gov)
    P3, N=259, Active, not recruiting, ITM Solucin GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)
    6ms
    Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
    P1, N=49, Recruiting, RayzeBio, Inc. | N=31 --> 49 | Trial primary completion date: Mar 2027 --> Jun 2027
    Enrollment change • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
    8ms
    Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Ariceum Therapeutics GmbH
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Zynyz (retifanlimab-dlwr) • SOMther (lutetium-177 DOTA satoreotide)
    8ms
    PROMENADE: Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (clinicaltrials.gov)
    P1/2, N=18, Recruiting, University Hospital, Basel, Switzerland | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Phase classification • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)
    8ms
    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). (PubMed, BMC Cancer)
    The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus.
    Clinical • Clinical protocol • Journal • HEOR
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    everolimus • Solucin (177Lu-edotreotide)